glp 1 mash approval FDA Expands Novo Nordisk's Wegovy to the Fatty Liver Disease What you need to know

This finding holds significant importance, noting that phase 3 studies have typically excluded patients with a history of psychiatric disorders, resulting in a lack of reference data for understanding the long-term consequences of GLP-1 RAs use in patients with obesity

Am J Physiol Physiol 297(6):F1647F1655 Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Container: Small (813 oz)

While early studies show safety and effectiveness, long-term impacts are still being researched

These drugs can also produce side effects that may spur changes in eating habits, which can lead to safety risks or worse health outcomes if not appropriately managed

GLP-1 drugs work by mimicking the hormone and keeping it around longer, which can aid in appetite suppression